We are live on ! Find out more
EDIT icon

Editas Medicine

229 hedge funds and large institutions have $1.35B invested in Editas Medicine in 2019 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 67 increasing their positions, 47 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 20

43% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 47

32% more capital invested

Capital invested by funds: $1.02B → $1.35B (+$331M)

22% more funds holding

Funds holding: 187229 (+42)

9% more call options, than puts

Call options by funds: $32M | Put options by funds: $29.3M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.66% less ownership

Funds ownership: 90.87%89.21% (-1.7%)

Holders
229
Holders Change
+42
Holders Change %
+22.46%
% of All Funds
4.51%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
64
Increased
67
Reduced
47
Closed
20
Calls
$32M
Puts
$29.3M
Net Calls
+$2.69M
Net Calls Change
+$9.77M
Name Holding Trade Value Shares
Change
Change in
Stake
ProShare Advisors
101
ProShare Advisors
Maryland
$536K -$23.8K -952 -5%
VF
102
Virtu Financial
New York
$535K +$451K +18,068 New
FWM
103
Focused Wealth Management
New York
$527K -$45.1K -1,804 -9%
Mirae Asset Global Investments
104
Mirae Asset Global Investments
South Korea
$524K +$60.4K +2,419 +16%
BPWA
105
Beacon Pointe Wealth Advisors
California
$515K
XK
106
Xact Kapitalforvaltning
Sweden
$515K +$435K +17,400 New
LTFS
107
Ladenburg Thalmann Financial Services
Florida
$505K +$45.1K +1,805 +12%
ECM
108
ExodusPoint Capital Management
New York
$494K +$417K +16,697 New
MLICM
109
Metropolitan Life Insurance Company (MetLife)
New York
$491K
NIT
110
NumerixS Investment Technologies
British Columbia, Canada
$483K +$331K +13,250 +434%
MWVC
111
Morgens Waterfall Vintiadis & Co
New York
$444K
RIA
112
Realta Investment Advisors
Delaware
$430K -$17.5K -699 -5%
DCM
113
Dupont Capital Management
Delaware
$398K
EAM
114
Erste Asset Management
Austria
$396K
Capital Fund Management (CFM)
115
Capital Fund Management (CFM)
France
$388K +$327K +13,087 New
FAIM
116
Financial Advocates Investment Management
Washington
$367K -$9.62K -385 -3%
M&T Bank
117
M&T Bank
New York
$350K -$524 -21 -0.2%
William Blair & Company
118
William Blair & Company
Illinois
$333K
CSS
119
Cubist Systematic Strategies
Connecticut
$327K +$276K +11,037 New
Walleye Trading
120
Walleye Trading
New York
$322K +$220K +8,791 +423%
Invesco
121
Invesco
Georgia
$314K -$17.5K -701 -6%
Wolverine Trading
122
Wolverine Trading
Illinois
$313K -$193K -7,743 -42%
AG
123
Aperio Group
California
$303K +$256K +10,233 New
SCA
124
Spearhead Capital Advisors
Florida
$296K +$249K +9,985 New
AB
125
Amalgamated Bank
New York
$285K +$18.2K +730 +8%

EDIT Hedge Fund Activity: Q4 2019 in Review

229 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2019, worth a combined $1.35B — up 32% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new EDIT positions and 20 closed out — a net gain of 44 holders — while 67 added to existing stakes and 47 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $10.8M. The largest seller was Ontario Teachers' Pension Plan Board, exiting entirely with an estimated $12.8M sold.

  • 229 institutional investors held Editas Medicine (EDIT) as of Q4 2019, up from 187 in Q3 2019.
  • Funds reported $1.35B of Editas Medicine stock for Q4 2019, up 32% quarter-over-quarter.
  • 64 funds opened new Editas Medicine positions in Q4 2019 and 20 closed out, a net change of +44 holders.
  • The largest Editas Medicine buyer in Q4 2019 was D.E. Shaw & Co, an estimated $10.8M added.
  • The largest Editas Medicine seller in Q4 2019 was Ontario Teachers' Pension Plan Board, an estimated $12.8M sold.

Based on aggregated 13F filings for Q4 2019.